# Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

> **NCT03600714** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 26 (actual)

## Conditions studied

- Liver Disease
- Hepatitis D

## Interventions

- **DRUG:** Peg-interferon lambda
- **DRUG:** Lonafarnib
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT03600714
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-01
- **Primary completion:** 2020-02-05
- **Final completion:** 2020-08-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03600714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03600714, "Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03600714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*